[go: up one dir, main page]

CO5200767A1 - Nueva forma cristalina de la sal disodica del acido n-[4-[2-(2- amino 4,7-dihidro-4-oxo-3h-pirrolo [2,3-d]- pirimidin-5-il] etil] benzoil]-l- glutamico y procedimiento para el mismo - Google Patents

Nueva forma cristalina de la sal disodica del acido n-[4-[2-(2- amino 4,7-dihidro-4-oxo-3h-pirrolo [2,3-d]- pirimidin-5-il] etil] benzoil]-l- glutamico y procedimiento para el mismo

Info

Publication number
CO5200767A1
CO5200767A1 CO00062633A CO00062633A CO5200767A1 CO 5200767 A1 CO5200767 A1 CO 5200767A1 CO 00062633 A CO00062633 A CO 00062633A CO 00062633 A CO00062633 A CO 00062633A CO 5200767 A1 CO5200767 A1 CO 5200767A1
Authority
CO
Colombia
Prior art keywords
glutamic
oxo
amino
pirimidin
pirrolo
Prior art date
Application number
CO00062633A
Other languages
English (en)
Inventor
Linda Marie Osborne
Van Den Berghe Snorek Sharon
Gregory Alan Stephenson
Anne Marie Warner
Erik Christopher Chelius
Original Assignee
Elililly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elililly And Company filed Critical Elililly And Company
Publication of CO5200767A1 publication Critical patent/CO5200767A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un procedimiento para la preparación de un compuesto de fórmula I<EMI FILE="00062633_1" ID="1" IMF=JPEG >que comprende hacer reaccionar pirrolo[2,3-d]-pirimidina sustituida en la posición 5 de fórmula III, en la que R es un grupo protector de carboxi:<EMI FILE="00062633_2" ID="2" IMF=JPEG >con hidróxido sódico.Una nueva forma cristalina hidratada de la sal disódica delácido N-[4-[2-(2-amino-4,7-dihidro-4-oxo-3H-pirrolo[2,3-d]-pirimidin-5-il)etil]benzoil]-L-glutámico ("MTA disódico hidratado Forma I") que presenta un diagrama de difracción de rayos X que comprende los siguientes picos correspondientes al espaciamiento d: 18,66 + 0,04 obtenido a 22 + 2 ºC y a una humedad relativa, en %, ambiental a partir de una fuente de radiación de cobre.
CO00062633A 1999-08-23 2000-08-22 Nueva forma cristalina de la sal disodica del acido n-[4-[2-(2- amino 4,7-dihidro-4-oxo-3h-pirrolo [2,3-d]- pirimidin-5-il] etil] benzoil]-l- glutamico y procedimiento para el mismo CO5200767A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15025499P 1999-08-23 1999-08-23
US18496400P 2000-02-25 2000-02-25

Publications (1)

Publication Number Publication Date
CO5200767A1 true CO5200767A1 (es) 2002-09-27

Family

ID=26847471

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00062633A CO5200767A1 (es) 1999-08-23 2000-08-22 Nueva forma cristalina de la sal disodica del acido n-[4-[2-(2- amino 4,7-dihidro-4-oxo-3h-pirrolo [2,3-d]- pirimidin-5-il] etil] benzoil]-l- glutamico y procedimiento para el mismo

Country Status (5)

Country Link
EP (1) EP1212325A2 (es)
AU (1) AU6890800A (es)
CO (1) CO5200767A1 (es)
PE (1) PE20010489A1 (es)
WO (1) WO2001014379A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02008242A (es) * 2000-02-25 2002-11-29 Lilly Co Eli Nueva forma cristalina del acido n-[4- [2-(2-amino -4, 7- dihidro -4 -oxo-3h- pirrolo [2, 3-d]pirimidin -5-il) eitl]benzoil] -l-glutamico y procedimiento para su obtencion.
EP1579857A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
WO2008021411A2 (en) 2006-08-14 2008-02-21 Sicor Inc. Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid
US7994180B2 (en) 2006-08-14 2011-08-09 Sicor Inc. Processes for preparing intermediates of pemetrexed
KR20090052355A (ko) 2006-08-14 2009-05-25 시코르, 인크. 순도가 높은 페메트렉세드 이산 및 이의 제조 방법
US8088919B2 (en) * 2006-08-14 2012-01-03 Sicor Inc. Crystalline forms of pemetrexed diacid and processes for the preparation thereof
MX2009010568A (es) * 2007-04-03 2009-10-22 Reddys Lab Ltd Dr Formas solidas de pemetrexed.
CN101417998B (zh) 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
US20090181990A1 (en) * 2007-12-23 2009-07-16 Patel Nileshkumar S Stable amorphous form of pemetrexed disodium
SI2985025T1 (en) * 2008-06-06 2018-04-30 Boehringer Ingelheim International Gmbh A pharmaceutical combination
EP2334685A4 (en) * 2008-09-08 2011-10-26 Reddys Lab Ltd Dr AMORPHOUS PEMETREXED DISODIUM
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
CN101684121B (zh) 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
TW201118098A (en) * 2009-08-13 2011-06-01 Reddy S Lab Liimited Dr Processes for preparing pemetrexed
CN102050825B (zh) * 2009-11-05 2014-12-17 上海创诺制药有限公司 制备培美曲塞二钠2.5水结晶的方法
US9174991B2 (en) 2009-11-24 2015-11-03 Azad Pharmaceutical Ingredients Ag Crystalline form of pemetrexed disodium
WO2012017443A1 (en) * 2010-08-02 2012-02-09 Neon Laboratories Ltd. Process for preparation of highly pure dialkyl pemetrexed
KR101308767B1 (ko) 2011-01-20 2013-12-31 에스티팜 주식회사 고 순도 페메트렉세드 디에틸 에스테르의 제조방법 및 이 방법을 포함하는 페메트렉세드 이나트륨염의 제조방법
WO2012111027A2 (en) * 2011-02-15 2012-08-23 Hetero Research Foundation Process for pemetrexed disodium
US9051322B2 (en) 2011-03-23 2015-06-09 Scinopharm Taiwan, Ltd. Process for the production of a pemetrexed salt
AU2011363636B2 (en) 2011-03-25 2016-03-17 Scinopharm Taiwan Ltd Process for the production of a pemetrexed salt
EP2909208A4 (en) * 2012-10-17 2016-07-13 Shilpa Medicare Ltd METHOD FOR PRODUCING PEMETREXED DIKALIUM AND ITS HYDRATES
US20150359898A1 (en) 2013-02-06 2015-12-17 Cipla Limited Pemetrexed Complexes and Pharmaceutical Compositions Containing Pemetrexed Complexes
WO2014185797A1 (en) 2013-05-17 2014-11-20 Instytut Farmaceutyczny Process for the preparation of high purity amorphous pemetrexed disodium and crystalline forms of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3- d] pyrimidin-5-yl)ethyl] benzoyl]-l-glutamic acid
WO2015008221A1 (en) 2013-07-16 2015-01-22 Dr. Reddy’S Laboratories Limited Novel crystalline forms of pemetrexed tromethamine salts
NZ630292A (en) * 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
CN103784454B (zh) * 2014-01-22 2015-11-18 海南锦瑞制药有限公司 一种含有培美曲塞二钠化合物的药物组合物
CN111954531A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化培美曲塞及其用途
JP7490239B2 (ja) 2018-02-07 2024-05-27 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化ペメトレキセドおよびその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0003954A3 (en) * 1997-09-26 2002-12-28 Lilly Co Eli Processes and intermediates useful to prepare pyrrolo [2,3-d] pyrimidine derivatives

Also Published As

Publication number Publication date
EP1212325A2 (en) 2002-06-12
AU6890800A (en) 2001-03-19
PE20010489A1 (es) 2001-04-27
WO2001014379A2 (en) 2001-03-01
WO2001014379A3 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
CO5200767A1 (es) Nueva forma cristalina de la sal disodica del acido n-[4-[2-(2- amino 4,7-dihidro-4-oxo-3h-pirrolo [2,3-d]- pirimidin-5-il] etil] benzoil]-l- glutamico y procedimiento para el mismo
AR073073A1 (es) Compuestos de pirrolo [ 2,3-d] pirimidina.
TERASHIMA et al. Studies on antiulcer agents. IV. Antiulcer effects of 2-benzylthio-5, 6, 7, 8-tetrahydro-4 (3H)-quinazolinones and related compounds
RU2001122164A (ru) Кристаллическая кальциевая соль бис[(е)-7-[4-(4-фторфенил)-6-изопропил-2-[метил(метилсульфонил)амино]- пиримидин-5-ил]-(3r,5s)-3,5-дигидроксигепт-6-еновой кислоты]
CO5670355A2 (es) Forma cristalina de sal de calcio de acido bis [(e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metilsulfonil)amino]pirimidin-5-il](3r,5s)-3,5-dihidroxihept-6-enoico
MY124784A (en) A novel crystalline form of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo [2,3-d] pyrimidin-5-yl) ethyl] benzoyl]-l-glutamic acid and proces therefor
BR0109577A (pt) Composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, método para tratar cânceres em um animal de sangue quente
LU90838I2 (fr) Zometa-acide zol-dronique et ses sels pharmaceutiquement acceptables
RU2006117337A (ru) Способ получения кальциевой соли розувастатина(е)-7-[4-(4-фторфенил)-6-изопропил-2-[метил(метилсульфонил)амино]пиримидин-5-ил](3r, 5s)-3, 5-дигидроксигепт-6-еновой кислоты и его кристаллических промежуточных соединений
CA2403514A1 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
AR005462A1 (es) Un proceso para preparar ciertos ciclohexapeptidos y compuestos obtenidos mediante dicho procedimiento.
CO5180605A1 (es) Compuestos de indol
TR200000786T2 (tr) Vitronektin reseptör antagonisti
GB0401336D0 (en) Organic compounds
CO5180567A1 (es) Sal polimor
BR0308018A (pt) Composto ou um seu sal farmaceuticamente aceitável ou um seu éster hidrolisável in vivo, pró-droga, método para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto ou um seu sal farmaceuticamente aceitável ou um seu éster hirolisável in vivo, composição farmacêutica, e, processo para a preparação de um composto ou um seu sal farmaceuticamente aceitável ou um seu éster hidrolisável in vivo
ES2091126T3 (es) Nuevos compuestos biciclicos de pirimidina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
IL195837A0 (en) 4-amino-3-arylamino-6-arylpyrazolo[3,4-d]
WO2005021511A1 (en) A novel process for amorphous rosuvastatin calcium
ES2167869T3 (es) Procedimiento para preparar acidos nicotinicos.
NO982107L (no) Fremstilling av et salt av klavulansyre
CO5170530A1 (es) Procedimietno para preparar derivados de 10,11-metanobenzosuberano
TR200003517T2 (tr) Amoksilin kristalin tuzlarını hazırlama prosesi
ES8500742A1 (es) Procedimiento para la preparacion de derivados de acido fenilacetico

Legal Events

Date Code Title Description
FA Application withdrawn